Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...
Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...
A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...
Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could ...
This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...
The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...
Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...
A Lilly investigational obesity pill largely helped patients maintain their weight loss after they switched from injectable ...
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback